Adverse Drug Events Associated with Low-Dose (10  mg) Versus High-Dose (25 mg) Empagliflozin in Patients Treated for Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

ConclusionsThe incidence of ADEs was not significantly different in T2DM patients receiving 10 versus 25  mg empagliflozin as monotherapy or as add-on to metformin or other anti-diabetic drugs during a shorter or longer follow-up period. However, genital and UTIs were more common in female patients with T2DM irrespective of empagliflozin dosage.
Source: Diabetes Therapy - Category: Endocrinology Source Type: research